title: Identification of residues involved in neurotensin binding and modeling of the agonist binding site in neurotensin receptor 1.
abstract: The neurotensin receptor 1 (NTR1) subtype belongs to the family of G protein-coupled receptors and mediates most of the known effects of the neuropeptide including modulation of central dopaminergic transmission. This suggested that nonpeptide agonist mimetics acting at the NTR1 might be helpful in the treatment of Parkinson's disease and schizophrenia. Here, we attempted to define the molecular interactions between neurotensin-(8-13), the pharmacophore of neurotensin, and the rat NTR1. Mutagenesis of the NTR1 identified residues that interact with neurotensin. Structure-activity studies with neurotensin-(8-13) analogs identified the peptide residues that interact with the mutated amino acids in the receptor. By taking these data into account, computer-assisted modeling techniques were used to build a tridimensional model of the neurotensin-(8-13)-binding site in which the N-terminal tetrapeptide of neurotensin-(8-13) fits in the third extracellular loop and the C-terminal dipeptide binds to residues at the junction between the extracellular and transmembrane domains of the receptor. Interestingly, the agonist binding site lies on top of the previously described NTR1-binding site for the nonpeptide neurotensin antagonist SR 48692. Our data provide a basis for understanding at the molecular level the agonist and antagonist binding modes and may help design nonpeptide agonist mimetics of the NTR1.
authors.affiliation: Institut de Pharmacologie Moléculaire et Cellulaire du CNRS, Université de Nice-Sophia Antipolis, Sophia Antipolis, 660 route des Lucioles, 06560 Valbonne, France.
authors.forename: S
authors.initials: S
authors.lastname: Barroso
authors.forename: F
authors.initials: F
authors.lastname: Richard
authors.forename: D
authors.initials: D
authors.lastname: Nicolas-Ethève
authors.forename: J L
authors.initials: JL
authors.lastname: Reversat
authors.forename: J M
authors.initials: JM
authors.lastname: Bernassau
authors.forename: P
authors.initials: P
authors.lastname: Kitabgi
authors.forename: C
authors.initials: C
authors.lastname: Labbé-Jullié
mesh_terms: D000596:Amino Acids / Q000235:genetics; D000818:Animals; D001665:Binding Sites; D001667:Binding, Competitive; D003198:Computer Simulation; D004305:Dose-Response Relationship, Drug; D007295:Inositol Phosphates / Q000378:metabolism; D008958:Models, Molecular; D016296:Mutagenesis; D009496:Neurotensin / Q000031:analogs & derivatives* / Q000378:metabolism; D011720:Pyrazoles / Q000494:pharmacology; D011804:Quinolines / Q000494:pharmacology; D051381:Rats; D018028:Receptors, Neurotensin / Q000819:agonists* / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D013329:Structure-Activity Relationship
chemical_list: D000596:Amino Acids; D007295:Inositol Phosphates; D011720:Pyrazoles; D011804:Quinolines; D018028:Receptors, Neurotensin; C114036:neurotensin type 1 receptor; C079087:SR 48692; D009496:Neurotensin